Member Info for liquid1

https://www.hemptouch.com/

When Kim Kardashian declares her love for a new beauty product, the world listens. So when the reality star and influencer recently took to Instagram to share her latest obsession - CBD cream - many UK fans were left wondering how to get their hands on some too. https://www.mirror.co.uk/3am/style/3am-fashion-celebrity-beauty/cbd-beauty-product-kim-kardashian-14105946

CBD is Integumen SKIN 20th February: This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema. 7th January CBD oil is an extract from the Cannabis Sativa plant. Cellulac (9.35% owned by Integumen) has developed a low-cost CBD oil extraction process and is collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics. Testing is underway using CBD oils of a quality comparable to that produced by Cellulac in an earlier proof of concept project. Results expected end of Q1 2019.

So when the reality star and influencer recently took to Instagram to share her latest obsession - CBD cream - many UK fans were left wondering how to get their hands on some too. In an Instagram story to her 130m followers, Kim posted a picture of a luxury beauty hamper captioned with the message: "Anyone that knows me knows I am obsessed with CBD everything!".

Great find pebsi! In an Instagram story to her 130m followers, Kim posted a picture of a luxury beauty hamper captioned with the message: "Anyone that knows me knows I am obsessed with CBD everything!". The hamper from a top Beverly Hills Spa featured beauty goodies including a jar of Pellequrx CBD Salve, which the salon uses in its luxury skin and facial treatments. While the premium salve, which helps topically treat skin conditions and irritations, isn't available in the UK, there are plenty of affordable dupes that offer similar benefits that shoppers can find on the high street.

20th February: This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema. 7th January CBD oil is an extract from the Cannabis Sativa plant. Cellulac (9.35% owned by Integumen) has developed a low-cost CBD oil extraction process and is collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics. Testing is underway using CBD oils of a quality comparable to that produced by Cellulac in an earlier proof of concept project. Results expected end of Q1 2019.

AI is the future of Labskin
Brandon isn’t standing still, either. With the help of artificial intelligence firm Rinocloud, he and his team are building Labskin-on-a-chip, which will record every treatment tested on the Labskin platform and store its effects in a database.

That will give every dermatology clinic with a computer, the ability to take a swab of a patient’s own skin bacteria, place it on the Labskin, run it against the database, and advise what the best course of treatment might be.

Then there’s Labskin AI, a digital extension to the lab-grown skin which Brandon likens to the life science equivalent of Airbnb.

It offers remote contract rental of laboratory equipment from service providers to buyers of those clinical test services, much like Airbnb matches holidaymakers with accommodation, without ever owning the house or apartment.

Brandon says the combination of Labskin-on-a-chip and Labskin AI should take Integumen to the next level as it is a combination of scaling as a software rather than a physical operation only, and he is targeting 150 companies with revenue in excess of £500mln.

That might sound ambitious, but Brandon reckons it is far from impossible.

“There are 3,685 companies that are large enough in the world to fit within that category. So, 150 is more than achievable.”

https://www.proactiveinvestors.co.uk/companies/news/216389/slimmed-down-integumen-looking-to-ai-for-next-stage-of-labskins-evolution-216389.html

“Instead of selling that proposition into companies as a test for sensitivity or allergens, we now offer the marketing department an opportunity to say, ‘our product can give you this benefit or that benefit’.”

As a result, clients who used to pay £2,000 for a simple test are now paying upwards of £50,000 to qualify claims about the impact of their product as an anti-ageing solution or balancing the skin’s good and bad bacteria.

That had an immediate effect on Integumen’s top-line: Labskin revenues totalled £149,000 in the first six months of 2018, but that figure surged by almost 350% in the second half of the year.

https://www.proactiveinvestors.co.uk/companies/news/216389/slimmed-down-integumen-looking-to-ai-for-next-stage-of-labskins-evolution-216389.html

Eczema & Achne results Q1 or March 2019!

@ 9:18 @ 2.39p Lovely!

Slimmed-down Integumen looking to AI for next stage of Labskin’s evolution

12:15 13 Mar 2019

Integumen’s Labskin technology has been used by some of the biggest names in pharma for years, but a small tweak in how it is sold has led to a surge in sales since new boss Gerry Brandon came in

https://www.proactiveinvestors.co.uk/companies/news/216389/slimmed-down-integumen-looking-to-ai-for-next-stage-of-labskins-evolution-216389.html

FFS MM's, if you don't want folks to buy move up the friggin price!

Anyone reckon that with 2 RNS due in March, sp can hit double digits??

Hence the current sp price dropping. They always know Applies to FDA and phase 3 drug results as well. Shit feeling :(((

Delayed Buy

Delayed! Why?? News not as good?

Going places this share.

Wait till Achne & Eczma results RNS Q1, ie: March 2019

Shares outstanding 456.67m
Free float 184.07m

No quotes

3 thing Q1:

CBD oil is an extract from the Cannabis Sativa plant. Cellulac (9.35% owned by Integumen) has developed a low-cost CBD oil extraction process and is collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics. Testing is underway using CBD oils of a quality comparable to that produced by Cellulac in an earlier proof of concept project. "Results expected end of Q1 2019".

"Results expected end of Q1 2019".

This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema.

"The Company is currently involved in a number of such discussions that may or may not lead to further accelerated expansion of the Company portfolio. Integumen will update the market with any new material information as appropriate in line with regulatory disclosure requirements."

https://www.youtube.com/watch?v=ge9MD_aXJOY

Integumen CEO hails firms' technology platform after transformational year

Proactive Investors Stocktube

Published on 6 Mar 2019

Gerry Brandon, chief executive of Integumen PLC (LON:SKIN), introduces the company to Proactive London's Andrew Scott and details their recent acquisition of hi-tech test equipment for their Labskin UK laboratories in York.

Brandon says the equipment connects directly to the Labskin Artificial Intelligence (AI) platform and will transform many of the current manual testing services into high-speed fully automated processes.